Newport Premium (for Innovators)

Powerful integrated API intelligence with unique analysis

Newport Premium (for Innovators) is the most advanced competitive intelligence, business development and global active pharmaceutical ingredient (API) sourcing system from Clarivate Analytics, the industry authority on the global generics market.

Spot the developing generic competition and find the opportunity.

Created specifically for demanding professionals in innovator, specialty and niche-brand pharmaceutical companies, it ensures you don’t miss the developing generic competition that can impact your sales, or the licensing opportunity that can build on your strengths. Its proven analytics can warn of potential generic activity four to seven years ahead of loss of exclusivity.

With its sophisticated product and company targeting capabilities, Newport Premium (for Innovators) can help you to identify, profile and evaluate licensing, acquisition and partnership opportunities. You can discover then niche opportunities that match your strategic needs and unique strengths in research, sales or marketing.

How you benefit

• Monthly intelligence updates
• Easy-to-use web-based interface
• Comprehensive training and technical support
• Integrated on-line help
• Zero cost deployment
• Secure, confidential hosted access

Clarivate Analytics
Where you can use it

- Company intelligence
- Business development and licensing
- Brand and lifecycle management
- Legal and intellectual property
- Product intelligence
- Company intelligence
- Patents
- Current Awareness

Competitive intelligence

- Identify the likely source, timing and impact of generic competition on your branded products.
- Detect and interpret the earliest signs of alternative form and polymorph development and API manufacturing.
- Quickly assess competitive dynamics for individual products, groups of products, or across therapy areas.
- Assess likely generic competitors and API suppliers by analyzing worldwide API consumption.

Business development and licensing

- Identify and evaluate global niche brands and candidate products for acquisition or licensing.
- Profile worldwide business partners for alliances, supply, out-licensing and manufacture.
- Identify likely primary or backup suppliers of APIs.

Brand and lifecycle management

- Determine if there are likely to be no generics, saving costly and perhaps needless line extension programs.
- Identify reliable, lower-cost, alternative or exclusive API sources for existing products.
- Improve planning of development pipelines
- Adjust sales and revenue forecasting based on the timing and extent of future generic competition.

Legal and intellectual property

- Spot potential patent challenges early.
- Formulate IP protection strategies at the earliest opportunity.
- Gather all the facts, before you hire costly specialist investigative firms and outside counsel.

Product intelligence

- Unique, early API manufacturing intelligence for 12,500 active ingredients
- Regulatory filings, such as US and Japanese DMFs, Certificates of Suitability, Indian and Chinese Import Registrations and US DEA registration notices
- Two years of regional sales and consumption data, worldwide launch, and pack price data for 140,000 products, 360,000 trade names in 70+ countries
- US Orange Book, EU centralized procedure, and European first market authorization data
- Chemical structure diagrams for thousands of products
- Routes of synthesis, including intermediates and reagents with patent and literature references for 3,000 products
- Worldwide manufacturer labels
- Global finished dose approval data

Source: ¹IMS Health, copyright 2012, all rights reserved
²Prous Science, a Clarivate Analytics business
• Powerful indexing and searching of products according to FDA approved indication and technology class
• Proprietary analytics

Company intelligence

• Profiles of more than 66,000 companies and corporate groups, including subsidiaries, finished dose launches, US approvals, regulatory filings, APIs manufactured, inspections by the US FDA and other regulatory agencies and Warning Letters
• Company key financial indicators and sales forecasts
• Proprietary company ratings

Patents

• Worldwide patent families and individual patents for more than 90 countries
• Comprehensive Supplementary Protection Certificate (SPC) data for Europe
• Projected loss of exclusivity dates for US, Australian, Canadian, South Korean, European and Japanese markets
• Paragraph IV patent challenges commentaries, including company identities, FTF and status of litigation for 500+ products with PIV commentaries

Current awareness

• E-mail alerting on key changes in products and companies, including new regulatory filings, approvals, and patent challenges
• Reports on key conferences covering the generics industry

To learn about our optional modules (US Market Share, Phase III Drugs, Generic Industry Deals, including mergers and acquisitions, and Biologics) that increase the power and value of Newport Premium (for Innovators) or our less extensive configurations, such as Newport Global (for Innovators) or Newport Sourcing visit clarivate.com/newport-premium
Who we are

Clarivate Analytics accelerates the pace of innovation by providing trusted insights and analytics to customers around the world, enabling them to discover, protect and commercialize new ideas faster. We own and operate a collection of leading subscription-based services focused on scientific and academic research, patent analytics and regulatory standards, pharmaceutical and biotech intelligence, trademark protection, domain brand protection and intellectual property management. Clarivate Analytics is now an independent company with over 4,000 employees, operating in more than 100 countries and owns well-known brands that include Web of Science, Cortellis, Derwent, CompuMark, MarkMonitor and Techstreet, among others. For more information, visit: clarivate.com

For more information:
clarivate.com/newport-premium